{"id":"https://openalex.org/W2019552174","doi":"https://doi.org/10.2147/ndt.s72642","title":"Efficacy comparison of duloxetine and SSRIs at doses approved in Japan","display_name":"Efficacy comparison of duloxetine and SSRIs at doses approved in Japan","alternate_titles":[],"publication_year":2015,"publication_date":"2015-01-01","ids":{"openalex":"https://openalex.org/W2019552174","doi":"https://doi.org/10.2147/ndt.s72642","mag":"2019552174","pmid":"https://pubmed.ncbi.nlm.nih.gov/25624763","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4296960"},"language":"en","primary_location":{"id":"doi:10.2147/ndt.s72642","doi":"https://doi.org/10.2147/ndt.s72642","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ndt.s72642","pdf_url":"https://www.dovepress.com/getfile.php?fileID=23224","source":{"id":"https://openalex.org/S124245730","display_name":"Neuropsychiatric Disease and Treatment","issn_l":"1176-6328","issn":["1176-6328","1178-2021"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuropsychiatric Disease and Treatment","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2019552174"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/getfile.php?fileID=23224","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5048936916","display_name":"Eiji Harada","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108315","display_name":"Eli Lilly (Japan)","ror":"https://ror.org/01sv7f575","country_code":"JP","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210108315"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Eiji Harada","raw_affiliation_strings":["Medical Science, Eli Lilly Japan K.K, Kobe, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Science, Eli Lilly Japan K.K, Kobe, Japan","institution_ids":["https://openalex.org/I4210108315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048043719","display_name":"Alexander Schacht","orcid":"https://orcid.org/0000-0001-9516-6262","observed_orcids":["https://orcid.org/0000-0001-9516-6262"]},"institutions":[{"id":"https://openalex.org/I4210110958","display_name":"Eli Lilly (Germany)","ror":"https://ror.org/01pmvz131","country_code":"DE","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210110958"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Alexander Schacht","raw_affiliation_strings":["Global Statistical Sciences, Eli Lilly and Company, Bad Homburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Statistical Sciences, Eli Lilly and Company, Bad Homburg, Germany","institution_ids":["https://openalex.org/I4210110958"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054302897","display_name":"Tsukasa Koyama","orcid":"https://orcid.org/0000-0002-8938-456X","observed_orcids":["https://orcid.org/0000-0002-8938-456X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tsukasa Koyama","raw_affiliation_strings":["Clinical Research Center, Ohyachi Hospital, Sapporo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research Center, Ohyachi Hospital, Sapporo, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061688954","display_name":"Lauren B. Marangell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I919571938","display_name":"The University of Texas Health Science Center at Houston","ror":"https://ror.org/03gds6c39","country_code":"US","type":"education","lineage":["https://openalex.org/I919571938"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lauren Marangell","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA ; The University of Texas Health Science Center, Houston, TX, USA","The University of Texas Health Science Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA ; The University of Texas Health Science Center, Houston, TX, USA","institution_ids":["https://openalex.org/I168537998","https://openalex.org/I919571938"]},{"raw_affiliation_string":"The University of Texas Health Science Center, Houston, TX, USA","institution_ids":["https://openalex.org/I919571938"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054311710","display_name":"Toshinaga Tsuji","orcid":"https://orcid.org/0000-0003-3685-0763","observed_orcids":["https://orcid.org/0000-0003-3685-0763"]},"institutions":[{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Toshinaga Tsuji","raw_affiliation_strings":["Medical Affairs, Shionogi & Co Ltd, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Affairs, Shionogi & Co Ltd, Osaka, Japan","institution_ids":["https://openalex.org/I4210118477"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5081820165","display_name":"Rodrigo Escobar","orcid":"https://orcid.org/0000-0003-4454-9399","observed_orcids":["https://orcid.org/0000-0003-4454-9399"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rodrigo Escobar","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5048936916"],"corresponding_institution_ids":["https://openalex.org/I4210108315"],"apc_list":{"value":2836,"currency":"USD","value_usd":2836},"apc_paid":{"value":2836,"currency":"USD","value_usd":2836},"fwci":0.5473,"has_fulltext":true,"cited_by_count":6,"citation_normalized_percentile":{"value":0.62862768,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":94},"biblio":{"volume":"11","issue":null,"first_page":"115","last_page":"115"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10853","display_name":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10272","display_name":"Mental Health Treatment and Access","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/duloxetine","display_name":"duloxetine","score":1.0},{"id":"https://openalex.org/keywords/selective-serotonin-reuptake-inhibitors","display_name":"selective serotonin reuptake inhibitors","score":0.9990000128746033},{"id":"https://openalex.org/keywords/paroxetine","display_name":"paroxetine","score":0.7749999761581421},{"id":"https://openalex.org/keywords/escitalopram","display_name":"escitalopram","score":1.0},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.9909999966621399},{"id":"https://openalex.org/keywords/antidepressant-efficacy","display_name":"antidepressant efficacy","score":0.9509999752044678},{"id":"https://openalex.org/keywords/individual-patient-data","display_name":"individual patient data","score":0.6650000214576721},{"id":"https://openalex.org/keywords/hamilton-depression-rating-scale","display_name":"Hamilton Depression Rating Scale","score":0.7620000243186951}],"concepts":[{"id":"https://openalex.org/C2780764818","wikidata":"https://www.wikidata.org/wiki/Q411932","display_name":"Duloxetine","level":3,"score":0.9799386262893677},{"id":"https://openalex.org/C2779583969","wikidata":"https://www.wikidata.org/wiki/Q423757","display_name":"Escitalopram","level":4,"score":0.8434395790100098},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7880618572235107},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7471047639846802},{"id":"https://openalex.org/C2777828372","wikidata":"https://www.wikidata.org/wiki/Q408471","display_name":"Paroxetine","level":4,"score":0.5978644490242004},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.5961105823516846},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.549605667591095},{"id":"https://openalex.org/C2910001868","wikidata":"https://www.wikidata.org/wiki/Q458","display_name":"European union","level":2,"score":0.506831705570221},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4968927204608917},{"id":"https://openalex.org/C31487548","wikidata":"https://www.wikidata.org/wiki/Q4859664","display_name":"Reuptake inhibitor","level":4,"score":0.4909510910511017},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.412663996219635},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.39803439378738403},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.27141252160072327},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.23337417840957642},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C105639569","wikidata":"https://www.wikidata.org/wiki/Q582577","display_name":"Economic policy","level":1,"score":0.0},{"id":"https://openalex.org/C2779144063","wikidata":"https://www.wikidata.org/wiki/Q338924","display_name":"Amygdala","level":2,"score":0.0},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.0},{"id":"https://openalex.org/C2781161787","wikidata":"https://www.wikidata.org/wiki/Q48360","display_name":"Hippocampus","level":2,"score":0.0}],"mesh":[],"locations_count":6,"locations":[{"id":"doi:10.2147/ndt.s72642","doi":"https://doi.org/10.2147/ndt.s72642","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ndt.s72642","pdf_url":"https://www.dovepress.com/getfile.php?fileID=23224","source":{"id":"https://openalex.org/S124245730","display_name":"Neuropsychiatric Disease and Treatment","issn_l":"1176-6328","issn":["1176-6328","1178-2021"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuropsychiatric Disease and Treatment","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:3271467","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/articles/PMC4296960","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmid:25624763","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25624763","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuropsychiatric disease and treatment","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4296960","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4296960/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuropsychiatr Dis Treat","raw_type":"Text"},{"id":"pmh:oai:dovepress.com/19945","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/efficacy-comparison-of-duloxetine-and-ssris-atnbspdoses-approved-in-ja-peer-reviewed-article-NDT","pdf_url":"https://www.dovepress.com/article/download/19945","source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:doaj.org/article:4adbe709deab40f798a54210e471a1f8","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/4adbe709deab40f798a54210e471a1f8","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Neuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 115-123 (2015)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.2147/ndt.s72642","doi":"https://doi.org/10.2147/ndt.s72642","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ndt.s72642","pdf_url":"https://www.dovepress.com/getfile.php?fileID=23224","source":{"id":"https://openalex.org/S124245730","display_name":"Neuropsychiatric Disease and Treatment","issn_l":"1176-6328","issn":["1176-6328","1178-2021"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuropsychiatric Disease and Treatment","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"},{"id":"https://openalex.org/F4320323024","display_name":"Astellas Pharma","ror":"https://ror.org/01cjash87"},{"id":"https://openalex.org/F4320323316","display_name":"Shionogi","ror":"https://ror.org/01v3bqg10"},{"id":"https://openalex.org/F4320333624","display_name":"Eli Lilly Japan","ror":"https://ror.org/01sv7f575"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2019552174.pdf","grobid_xml":"https://content.openalex.org/works/W2019552174.grobid-xml"},"referenced_works_count":25,"referenced_works":["https://openalex.org/W70904255","https://openalex.org/W1756919484","https://openalex.org/W1930767620","https://openalex.org/W1990161259","https://openalex.org/W1994256806","https://openalex.org/W1996039326","https://openalex.org/W2011390619","https://openalex.org/W2015700432","https://openalex.org/W2019015777","https://openalex.org/W2025918112","https://openalex.org/W2051675429","https://openalex.org/W2082270426","https://openalex.org/W2098354008","https://openalex.org/W2107786290","https://openalex.org/W2114613490","https://openalex.org/W2121017483","https://openalex.org/W2132577167","https://openalex.org/W2141398558","https://openalex.org/W2149154629","https://openalex.org/W2160070901","https://openalex.org/W2319982487","https://openalex.org/W2405443059","https://openalex.org/W2419272754","https://openalex.org/W2493886745","https://openalex.org/W2800259946"],"related_works":["https://openalex.org/W2744626855","https://openalex.org/W2011390619","https://openalex.org/W2048031361","https://openalex.org/W1591705123","https://openalex.org/W2972543417","https://openalex.org/W1994256806","https://openalex.org/W1594168967","https://openalex.org/W2159484656","https://openalex.org/W2742600600","https://openalex.org/W4391607833"],"abstract_inverted_index":{"BACKGROUND:":[0],"Approved":[1],"doses":[2,29,75],"of":[3,45,55,63,67,260,267],"antidepressants":[4,23],"in":[5,12,31,77,98,114,126,151,175,182,201,233,257,276,284],"Japan":[6,99,234],"are":[7],"usually":[8],"lower":[9],"than":[10],"those":[11,66],"the":[13,27,32,61,74,94,127,143,184,188,203,229,265,290],"USA":[14,33],"and":[15,34,37,112,160,165,187,242,262,289,308],"European":[16,35],"Union,":[17],"but":[18,282],"to":[19,49,59,173,199,280,295,305],"date":[20],"meta-analyses":[21],"comparing":[22],"have":[24,39],"all":[25],"used":[26,40],"higher":[28],"approved":[30,76,97,232],"Union":[36],"often":[38],"indirect":[41,309],"comparisons.":[42,310],"The":[43,138],"purpose":[44],"this":[46,270],"study":[47],"was":[48,142,197],"conduct":[50],"an":[51],"integrated":[52],"database":[53],"analysis":[54,128,271],"patient":[56,287],"level":[57],"data":[58,81,288,301],"compare":[60],"effects":[62],"duloxetine":[64,92,241,256],"with":[65,102,116,237,251],"selective":[68,131,167,243],"serotonin":[69,132,168,244],"reuptake":[70,133,169,245],"inhibitors":[71,170,246],"(SSRIs)":[72],"at":[73,93,148,179],"Japan.":[78],"METHODS:":[79],"Pooled":[80],"were":[82,124,171],"analyzed":[83],"from":[84,146],"four":[85],"randomized,":[86],"double-blind,":[87],"placebo-controlled":[88],"studies":[89,294],"that":[90],"compared":[91],"dose":[95,230],"range":[96,231],"(40-60":[100],"mg/day)":[101,111],"other":[103],"SSRIs":[104,200],"(paroxetine":[105],"20":[106],"mg/day":[107],"or":[108],"escitalopram":[109],"10":[110],"placebo":[113,174],"patients":[115,123,236],"major":[117,238],"depressive":[118,239],"disorder.":[119],"In":[120],"total,":[121],"1,694":[122],"included":[125],"(duloxetine,":[129],"n=688;":[130],"inhibitors,":[134],"n=690;":[135],"placebo,":[136],"n=316).":[137],"primary":[139],"outcome":[140],"measure":[141],"mean":[144,210],"change":[145],"baseline":[147],"week":[149,180],"8":[150,181],"17-item":[152],"Hamilton":[153],"Rating":[154],"Scale":[155],"for":[156,235,255,297],"Depression":[157],"(HAMD17)":[158],"total":[159,177,193],"subscale":[161,206],"scores.":[162],"RESULTS:":[163],"Duloxetine":[164,196],"both":[166,183],"superior":[172,198],"HAMD17":[176,204],"score":[178,207],"all-randomized":[185,215],"group":[186],"more":[189],"severe":[190,221],"subgroup":[191],"(HAMD17":[192],"scores":[194],"\u226519).":[195],"improving":[202,258],"Retardation":[205],"(least":[208],"squares":[209],"difference":[211],"[95%":[212],"confidence":[213],"interval]):":[214],"group,":[216],"-0.33":[217],"[-0.60,":[218],"-0.07],":[219,225],"P=0.015;":[220],"subgroup,":[222],"-0.45":[223],"[-0.83,":[224],"P=0.020).":[226],"CONCLUSION:":[227],"Within":[228],"disorder,":[240],"demonstrated":[247],"comparable":[248],"overall":[249],"efficacy,":[250],"a":[252],"possible":[253],"advantage":[254],"loss":[259],"energy":[261],"interest.":[263],"To":[264],"best":[266],"our":[268],"knowledge,":[269],"is":[272],"unique":[273],"not":[274],"only":[275],"evaluating":[277],"dosages":[278],"specific":[279],"Japan,":[281],"also":[283],"using":[285],"individual":[286],"same":[291],"endpoint":[292],"across":[293],"allow":[296],"strictly":[298],"direct":[299,307],"head-to-head":[300],"comparisons":[302],"as":[303],"opposed":[304],"pooling":[306]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2019552174","counts_by_year":[{"year":2023,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1}],"updated_date":"2026-11-18T13:11:19.462570","created_date":"2016-06-24T00:00:00"}
